Investors Buy Large Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) was the recipient of unusually large options trading activity on Wednesday. Investors acquired 1,002 put options on the company. This is an increase of 1,791% compared to the typical volume of 53 put options.

Analysts Set New Price Targets

A number of research firms have weighed in on MRVI. Weiss Ratings restated a “sell (d-)” rating on shares of Maravai LifeSciences in a report on Tuesday, October 14th. Wells Fargo & Company boosted their target price on shares of Maravai LifeSciences from $4.00 to $4.50 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Four equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $5.25.

Insiders Place Their Bets

In related news, CEO Bernd Brust purchased 216,212 shares of the stock in a transaction that occurred on Thursday, November 13th. The stock was purchased at an average cost of $3.25 per share, for a total transaction of $702,689.00. Following the acquisition, the chief executive officer owned 466,771 shares in the company, valued at approximately $1,517,005.75. This trade represents a 86.29% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gregory T. Lucier acquired 48,528 shares of the business’s stock in a transaction on Monday, December 8th. The stock was bought at an average cost of $3.67 per share, for a total transaction of $178,097.76. Following the completion of the transaction, the director directly owned 155,123 shares of the company’s stock, valued at $569,301.41. This trade represents a 45.53% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders have purchased 566,771 shares of company stock valued at $1,880,244. 2.11% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Maravai LifeSciences

Several large investors have recently modified their holdings of MRVI. 12 West Capital Management LP grew its stake in Maravai LifeSciences by 8.0% in the first quarter. 12 West Capital Management LP now owns 12,521,335 shares of the company’s stock worth $27,672,000 after purchasing an additional 930,000 shares in the last quarter. Mirabella Financial Services LLP grew its position in shares of Maravai LifeSciences by 0.3% in the 2nd quarter. Mirabella Financial Services LLP now owns 3,750,000 shares of the company’s stock worth $9,038,000 after acquiring an additional 10,049 shares in the last quarter. Monaco Asset Management SAM increased its holdings in shares of Maravai LifeSciences by 315.0% in the 3rd quarter. Monaco Asset Management SAM now owns 3,656,337 shares of the company’s stock valued at $10,494,000 after acquiring an additional 2,775,372 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Maravai LifeSciences by 12.0% in the 2nd quarter. Geode Capital Management LLC now owns 2,984,045 shares of the company’s stock valued at $7,193,000 after acquiring an additional 319,679 shares during the last quarter. Finally, Philosophy Capital Management LLC acquired a new stake in shares of Maravai LifeSciences during the 1st quarter valued at approximately $5,731,000. Institutional investors own 50.25% of the company’s stock.

Maravai LifeSciences Stock Performance

Shares of MRVI opened at $3.31 on Thursday. Maravai LifeSciences has a 52-week low of $1.66 and a 52-week high of $6.21. The company has a quick ratio of 4.56, a current ratio of 5.29 and a debt-to-equity ratio of 0.74. The firm has a market cap of $845.12 million, a price-to-earnings ratio of -3.93 and a beta of 0.33. The business’s 50 day moving average is $3.41 and its two-hundred day moving average is $2.87.

Maravai LifeSciences (NASDAQ:MRVI) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). Maravai LifeSciences had a negative return on equity of 22.42% and a negative net margin of 62.88%.The company had revenue of $41.63 million during the quarter, compared to the consensus estimate of $49.02 million. Analysts forecast that Maravai LifeSciences will post -0.24 EPS for the current fiscal year.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.